The Theodore Roosevelt National Park Wild Horses Protection Act requires the Department of the Interior to keep at least 150 genetically diverse wild horses in the South Unit of Theodore Roosevelt National Park. The department must create a management plan to protect these horses while also safeguarding the park's natural resources. Horses can only be removed from the park under specific conditions, such as to maintain genetic diversity, in emergencies, or for public health and safety reasons. The department is also required to monitor and report on the horses' population and health each year.
Supporters of the bill have praised it for its commitment to preserving the wild horse population at Theodore Roosevelt National Park, highlighting the importance of maintaining genetic diversity and promoting ecological balance. Conservation groups have expressed enthusiasm for the legislation, viewing it as a significant step towards protecting wildlife and natural heritage in the region.
Critics of the bill have raised concerns about the feasibility of maintaining a wild horse population of at least 150 individuals, arguing that it could lead to overpopulation issues and potential harm to the park's ecosystem. Some have also questioned the effectiveness of the proposed management plan, fearing that it might not adequately address the complexities of balancing wildlife preservation with environmental sustainability.
The Theodore Roosevelt National Park Wild Horses Protection Act, sponsored by John Hoeven, does not exhibit any direct industry overlaps with the sponsor's top donor industries, which include Health Professionals and Retired individuals. The total contributions from these industries amount to $1.26 billion, but they do not relate to the subject matter of the bill, which focuses on wildlife protection rather than healthcare or retirement issues. Furthermore, the lobbying activity in the bill's policy area primarily involves undisclosed amounts from various entities, with only a few specific dollar amounts reported, such as $5,000 from Amgen Inc. and $90,000 from Grand Pharmaceutical Group Ltd. This suggests that while there is some lobbying activity, it does not directly connect to the sponsor's financial backers or the bill's objectives, indicating a low risk of conflict of interest.
Organizations that lobbied on issues related to this bill's policy area.
| Client | Lobbying Firm | Amount |
|---|---|---|
| GRAND PHARMACEUTICAL GROUP LTD (FKA EAST OCEAN MEDICAL (HONG KONG) LIMITED) | CHECKMATE GOVERNMENT RELATIONS | $90,000 |
| ROCKY MOUNTAIN ELK FOUNDATION | DOUBLE HAUL STRATEGIES LLC | $9,000 |
| AMGEN INC. | WASHINGTON ADVOCACY GROUP | $5,000 |
| FUEL ETHANOL DISRUPTIVE BIOTECHNOLOGY RESEARCH CENTER INCORPATED | MR. AMIR GOULART SCHARIF | undisclosed |
| FUEL ETHANOL DISRUPTIVE BIOTECHNOLOGY RESEARCH CENTER INCORPATED | MR. AMIR GOULART SCHARIF | undisclosed |
| BLACKSTONE CONSTRUCTION LLC | WASHINGTON ADVOCACY GROUP | undisclosed |
| DENALI WATER SOLUTIONS | WASHINGTON ADVOCACY GROUP | undisclosed |
| NATIONAL ASSOCIATION OF PROFESSIONAL EMPLOYER ORGANIZATIONS (NAPEO) | ARENTFOX SCHIFF LLP | undisclosed |
| RROMA COUNCIL | RROMA COUNCIL | undisclosed |
| BAJO COHEN AGLIANO, P.A. ON BEHALF OF HEALTH EDGE INVESTMENT PARTNERS, LLC | BALLARD PARTNERS | undisclosed |
| ERUDIO BIO, INC. | BALLARD PARTNERS | undisclosed |
| THE LOUIS D. BRANDEIS CENTER FOR HUMAN RIGHTS UNDER LAW | THE LOUIS D. BRANDEIS CENTER FOR HUMAN RIGHTS UNDER LAW | undisclosed |
| CELLIGENCE LLC | BALLARD PARTNERS | undisclosed |
| PENN ENTERTAINMENT, INC. | BALLARD PARTNERS | undisclosed |
| COMMUNITY BANK ADVISORY SERVICES, LLC | COMMUNITY BANK ADVISORY SERVICES, LLC | undisclosed |
Source: Senate Lobbying Disclosure Act (LDA) filings, 2026
Top industries funding John Hoeven, ranked by total contributions.
Source: OpenSecrets.org (Center for Responsive Politics)
